Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
IPO Year: 2004
Exchange: NASDAQ
Website: dynavax.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2024 | $20.00 | Neutral | Goldman |
9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
1/6/2022 | $38.00 | Buy | Goldman |
12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
8/6/2021 | $19.00 | Buy | Goldman Sachs |
8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 price target.
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 price target.
Tuesday, Dynavax Technologies Corporation (NASDAQ:DVAX) provided a regulatory update for its supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis. The FDA has issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose regimen of HEPLISAV-B. The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and Great Britain, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The CRL also does not affect the approval decisi
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 price target.
HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany HEPLISAV-B gross margin of approximately 80%
Dynavax Technologies (NASDAQ:DVAX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. The company reported quarterly sales of $50.790 million which missed the analyst consensus estimate of $54.975 million by 7.61 percent. This is a 8.24 percent increase over sales of $46.925 million the same period last year.
S-8 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
10-Q - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
10-Q - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
ARS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-yearReaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionInitiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 6, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2024.
EMERYVILLE, Calif., July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors
EMERYVILLE, Calif., June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus. "We believe there is an opportunity to develop an improved
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CTGoldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ETThe presentations will be webcast and may be accessed through the "Events & Presentations" page
EMERYVILLE, Calif., May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the sBLA, stating that the application did not provide sufficient data to support the full evaluation of effectiveness or safety of a four-dose regimen of HEPLISAV-B. The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and Gre
HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionAnnounces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles programConference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., May 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, May 8, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.d
EMERYVILLE, Calif., Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET. The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About Dynavax Dynavax is a commercial-stage biopharmac
HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 millionAchieved market leader status in key segments retail pharmacy and IDNs in 20232024 HEPLISAV-B net product revenue expected to be $265 - $280 millionCash position increased to $742 million at year end and expect to be cash flow positive for full year 2024Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., Feb. 22, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
3 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-yearReaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionInitiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 6, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2024.
EMERYVILLE, Calif., July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors
HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 millionAnnounces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles programConference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., May 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, May 8, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.d
HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 millionAchieved market leader status in key segments retail pharmacy and IDNs in 20232024 HEPLISAV-B net product revenue expected to be $265 - $280 millionCash position increased to $742 million at year end and expect to be cash flow positive for full year 2024Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., Feb. 22, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.
EMERYVILLE, Calif., Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 22, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website
Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increaseFull year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 millionCash and investments increased to $682 million at quarter end; expects positive free cash flow for full yearConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 3, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2023.
EMERYVILLE, Calif., July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investo
HEPLISAV-B® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47%Strengthened balance sheet with cash and investments of $652 million at quarter end and expects positive free cash flow in 2023Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for th
EMERYVILLE, Calif., April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 2, 2023, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav
Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00
JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00
Goldman resumed coverage of Dynavax with a rating of Buy and set a new price target of $38.00
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $28.00 from $23.00 previously
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $23.00 from $20.00 previously
Goldman Sachs initiated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $19.00
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $20.00 from $16.00 previously
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $15.00 from $14.00 previously
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h
EMERYVILLE, Calif., Dec. 14, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines to protect the world against infectious diseases, today announced the appointment of Elaine Sun to its Board of Directors. "We are delighted to welcome Elaine to our Board of Directors. Her strategic, operational and financial experience in the life sciences industry will be a strong addition to our current Board," commented Ryan Spencer, Chief Executive Officer of Dynavax. "We look forward to El
EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Scott Myers to its Board of Directors. Mr. Myers was also elected Board Chairman, succeeding Dr. Andrew Hack who has served as interim Chairman of the Board since May 2020. Dr. Hack will continue to serve on the Board of Directors. "I am excited to have Scott join the Board of Directors as he brings tremendous depth and breadth of highly relevant experience as
EMERYVILLE, Calif., June 29, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021, the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock. The stock option has a 7-year term and vests over three years, with one-third of the shares underlying the option vesting on the one-year anniversary of the grant date, and the remaining shares vesting 1/36 per month in equal installments, subject t
EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Kelly MacDonald has been appointed Senior Vice President and Chief Financial Officer. Ms. MacDonald will join the company effective March 1, 2021. As previously announced, after 14 years at Dynavax, Chief Financial Officer Michael Ostrach is retiring. Mr. Ostrach has agreed to remain available as an advisor to the Company thereafter. Dynavax Appoints Kelly MacDonald as Chief Financial Officer "Michael's contributions and unwavering commitment to Dynavax have been critic
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi